Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
This study evaluates the diagnostic performance and safety of \[18F\]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
Prostate Cancer|Prostate Cancer Recurrent
DRUG: [18F]PSMA-1007
Region-level positive predictive value (PPV) of [18F]PSMA-1007 using a combined standard of truth (SOT), Within 6 months after PET/CT|Patient-level correct detection rate of [18F]PSMA-1007, Within 6 months after PET/CT
This study evaluates the diagnostic performance and safety of \[18F\]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.